Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effektivitets- og sikkerhetsstudie av Tisagenlecleucel hos brasilianske pasienter med akutt lymfoblastisk leukemi eller diffust stort B-cellet lymfom

9. november 2026 oppdatert av: Novartis Pharmaceuticals

Effektiviteten og sikkerheten til Tisagenlecleucel-terapi hos brasilianske pasienter med akutt lymfoblastisk leukemi eller diffust stort B-celle lymfom: en 15-årig prospektiv registerstudie på to kohorter

This will be a multicenter, national, non-interventional, prospective cohort study

Studieoversikt

Detaljert beskrivelse

Eligible participants will be pediatric (<18 years) and adult patients (aged 18 years or older) with B-cell malignancies who have received tisagenlecleucel through the commercial setting or out-of-specification (OOS) use in Brazil. We will collect data prospectively and complement missing information with retrospective data collection, when necessary. It is anticipated that approximately 200 patients will be enrolled in the cohort over 5 years divided among the study indications.

Since this is a non-interventional study, no administration of study drug or application of questionnaires will be mandated by this protocol. The study will consist of a "Pre-infusion" and a "Post infusion follow-up period" for up to 15 years post tisagenlecleucel infusion. All patients will be followed until death or last scheduled visit, whichever comes first.

For the study, "pre-infusion" and "follow-up post infusion" phases are defined as:

  • "Pre-infusion" will consist of the patient's information from the time of diagnosis untiljust prior to infusion with tisagenlecleucel.
  • "Follow-up Post infusion" information will comprise any information from the infusionof tisagenlecleucel onwards.

Studietype

Observasjonsmessig

Registrering (Antatt)

200

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

  • Navn: Novartis Pharmaceuticals

Studiesteder

      • São Paulo, Brasil, 01509-010
        • Rekruttering
        • Novartis Investigative Site
      • São Paulo, Brasil, 01409-902
        • Rekruttering
        • Novartis Investigative Site
    • Belo Horizonte
      • Minas Gerais, Belo Horizonte, Brasil, 34006-059
        • Rekruttering
        • Novartis Investigative Site
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasil, 41253-190
        • Rekruttering
        • Novartis Investigative Site
    • Paraná
      • Curitiba, Paraná, Brasil, 81520-060
        • Rekruttering
        • Novartis Investigative Site
    • São Paulo
      • São Paulo, São Paulo, Brasil, 01323-900
        • Rekruttering
        • Novartis Investigative Site
      • São Paulo, São Paulo, Brasil, 04544-000
        • Rekruttering
        • Novartis Investigative Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

1 sekund til 100 år (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

The study population will include pediatric/ adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia aged 0-25 years and adult patients aged ≥ 18 years with relapsed/refractory Diffuse Large B-cell Lymphoma and relapsed/refractory follicular lymphoma, who received tisagenlecleucel infusion in the commercial setting or out-of-specification.

Beskrivelse

Inclusion Criteria:

Patients eligible for inclusion in this study must meet the following criteria:

  1. Patients who receive tisagenlecleucel infusion in the commercial setting or out-of-specification (OOS) use, AND

  2. Signed informed consent must be obtained prior to participation in study, AND

    For ALL participants:

  3. Patients of any gender aged 0-17 years (named as pediatric) with relapsed/ refractory B-cell ALL diagnosis that received tisagenlecleucel infusion, OR

  4. Patients of any gender, aged 18-25 years (named as adults) - with relapsed/ refractory B-cell ALL diagnosis that received tisagenlecleucel infusion, OR

    For DBLCL and FL participants:

  5. Patients of any gender aged 18 years or older, who have been diagnosed with relapsed/ refractory Diffuse Large B-cell Lymphoma and received tisagenlecleucel infusion.

Exclusion Criteria:

  1. Patients who did not consent to data collection.
  2. Patients who received tisagenlecleucel infusion as part of any interventional clinical trial.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: OTHER

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Acute Lymphoblastic Leukemia (ALL)

Children/young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia who received tisagenlecleucel infusion

Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study

Diffuse Large B-cell Lymphoma (DLBCL)

Adult patients with relapsed/refractory Diffuse Large B-cell Lymphoma who received tisagenlecleucel infusion

Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study

Follicular Lymphoma (FL)

Patients of any gender aged 18 year or older, with relapsed/refractory Follicular Lymphoma who received tisagenlecleucel infusion.

Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Overall response rate (ORR)
Tidsramme: Up to 15 years

The overall response rate will be defined as the total proportion of participants exhibiting either the best overall response (BOR) of complete or partial responses and the proportion of patient with BOR of CR/PR or CR/CRi for ALL patients will be reported along with its 95% CI.

For ALL participants, the BOR will be defined as a CR or a CRi in accordance with National Comprehensive Cancer Network (NCCN) guidelines and previous guidelines (Appelbaum et al 2007)(Cheson et al 2003).

For lymphomas, the BOR will be defined as a CR or PR in accordance with the Cheson response criteria (Cheson et al 2007) and the Lugano classification (Cheson et al 2016).

Up to 15 years
MRD negative overall response rate
Tidsramme: Up to 15 years

The percentage of B-cell ALL patients who achieve a Best Overall Response (BOR) of CR or CRi with a Minimal residual disease (MRD) negative bone marrow will be provided with 95% CI.

Up to 15 years
Duration of overall response (DOR)
Tidsramme: Up to 15 years

Duration of overall response (DOR) applies only to patients whose best overall disease response was either:

  • CR or PR for patients with lymphomas, or
  • CR or a CRi for patients with ALL.

DOR will be defined as the time from the date of first documented disease response (Complete Response (CR) or PR for patients with lymphomas, and Complete Remission (CR) or CRi for patients with ALL), whichever occurs first, to the date of first documented progression or first documented relapse according to indication, or to the date of death due to the underlying disease.

In case a patient does not have progression/relapse or death due to underlying disease (defined as the event for this outcome) prior to data cut-off, DOR will be censored at the date of the last assessment on or prior to the earliest censoring event.

Up to 15 years
Relapse-free survival (RFS)
Tidsramme: Up to 15 years

RFS is measured by the time from date of first documented disease response as CR or CRi to relapse or death due to any cause in ALL patients.

In case a patient does not have relapse or death due to any cause prior to data cutoff, RFS will be censored at the date of the last adequate assessment on or prior to the earliest censoring event.

Up to 15 years
Event-free survival (EFS) for ALL patients
Tidsramme: Up to 15 years

EFS is the time from date of first tisagenlecleucel infusion to treatment failure, relapse or death from any cause, whichever occurred first, for B-cell ALL patients.

Up to 15 years
Progression free survival (PFS) for DLBCL patients
Tidsramme: Up to 15 years

PFS is defined as the time from the date of first infusion to the date of event defined as the first documented progression of lymphoma or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of the last adequate assessment.

In case a patient does not have progression or death prior to data cutoff, PFS will be censored at the date of the last adequate assessment on or prior to the earliest censoring event.

Up to 15 years
Overall survival (OS)
Tidsramme: Up to 15 years

Overall survival is the time from date of first tisagenlecleucel infusion to the date of death due to any reason, In case a patient is alive at the date of last contact on or before data cutoff, OS is censored at the date of last contact.

Up to 15 years
Number of ALL patients with hematologic recovery
Tidsramme: Up to 15 years

Dates of hematological recovery (i.e., dates of Absolute Neutrophil Count (ANC) and platelet recovery) will be collected.

ANC recovery is defined as an ANC of ≥ 0.5 × 109/L (500/mm^3) for 3 consecutive laboratory values obtained on different days. Date of ANC recovery is the date of the first of 3 consecutive laboratory values where the ANC is ≥ 0.5 × 109/L (CIBMTR).

The first date of the 3 consecutive laboratory values obtained on different days where the platelet count was ≥ 20 × 109/L should be recorded. It should be ensured that no platelet transfusions were administered for 7 days immediately preceding this date (CIBMTR).

Up to 15 years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
The type and frequency of SAEs and AE of special interest
Tidsramme: Up to 15 years

The type and frequency of SAEs and AE of special interest (including secondary malignancies) will be collected

Up to 15 years
Incidence and severity of CRS and ICANS among HTLV 1 and 2 positive versus HTLV 1 and 2 negative patients
Tidsramme: Up to 15 years

Incidence and severity of Cytokine release syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) among Human T-cell Lymphotropic Virus (HTLV) 1 and 2 positive versus HTLV 1 and 2 negative patients.

For CRS AE the protocol will follow the American Society of Transplant and Cellular Therapy (ASTCT) CRS Consensus Grading.

For ICANS AE the protocol will follow ASTCT consensus as well. Which establishes the Immune effector Cell-associated Encephalopathy (ICE Score) for adults/ adolescents and Cornell Assessment of Pediatric Delirium (CAPD) for pediatric patients under 12 years

Up to 15 years
Pregnancy rates
Tidsramme: Up to 15 years

Pregnancy rates will be collected

Up to 15 years
Number of patients with confirmed secondary malignancies diagnosis
Tidsramme: Up to 15 years

Number of patients with confirmed secondary malignancies diagnosis will be collected

Up to 15 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

24. november 2023

Primær fullføring (Antatt)

23. november 2037

Studiet fullført (Antatt)

23. november 2037

Datoer for studieregistrering

Først innsendt

13. september 2022

Først innsendt som oppfylte QC-kriteriene

13. september 2022

Først lagt ut (Faktiske)

15. september 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere